MedTrace Logo

Study of SARS-CoV2 Virus (COVID-19) Seroprevalence in the Population of Creil Air Force Base (BA110)

NCT04404270 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1146

Last updated 2021-07-07

No results posted yet for this study

Summary

In mid-February 2020, within the Oise (France) cluster, a case of COVID-19 disease caused by a SARS-CoV2 infection was described among the personnel of the Creail Air Force Base (BA110). This resulted in the beginning of an epidemic controlled by epidemiological measures. One month later, containment measures were taken at the national level, measures that also applied to BA110 personnel. These personnel, exposed to both the initial phase of the epidemic and national protection measures, represent an extremely interesting population for understanding the epidemiological dynamics of the virus, particularly at a time when France is lifting the containment measures. It becomes extremely important to understand the levers of viral spread in order to adjust the health measures to be maintained as best as possible.

The main objective of this study is to determine the extent of virus diffusion in this highly circulating population, as evidenced by several identified cases of COVID-19.

Conditions

  • Sars-CoV2

Interventions

DIAGNOSTIC_TEST

Anti-SARS-CoV2 Serology

The anti-SARS-CoV2 serological status will be measured on a blood sample collected at Day 0.

BEHAVIORAL

Questionnaire

Epidemiological data will be collected in a questionnaire that will be filled by participants at Day 0 (Visit 1), after 3 months (Visit 2) and after 9 months (Visit 3). The questionnaire includes: * medical data (height, weight, smoking, history of intense stress); * socio-demographic data (age, gender, civil/military status, function/occupation, rank category, army, family status/home composition, housing conditions, etc.); * clinical data : history of symptoms suggestive of COVID-19 in the last 3 months, current symptoms suggestive of COVID-19; * use of care, hospitalization, work stoppage in the last 3 months; * contact with people who are symptomatic or proven COVID-19.

DIAGNOSTIC_TEST

Anti-SARS-CoV2 serological controls and serum neutralization

Serological controls and a serum neutralization test will be performed on blood samples collected 3 months (Visit 2) and 9 months (Visit 3) after Day 0, respectively.

Sponsors & Collaborators

  • Direction Centrale du Service de Santé des Armées

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-05-26
Primary Completion
2021-03-13
Completion
2021-03-13

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04404270 on ClinicalTrials.gov